Atlas Trials

Ruxolitinib in Estrogen Receptor Positive Breast Cancer

Clinical trial NCT01594216 · COMPLETED

Trial details

NCT number
NCT01594216
Sponsor
Abramson Cancer Center at Penn Medicine
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Estrogen-receptor Positive Invasive Metastatic Breast Cancer
Start date
2012-04-01
Primary completion
2016-04-01
Enrollment
25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.